|Publisher||: Academic Press|
|Release Date||: 2018-11-21|
|ISBN 10||: 0128127384|
|Pages||: 292 pages|
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment
|Publisher||: Academic Press|
|Release Date||: 2019-11-07|
|ISBN 10||: 0128141417|
|Pages||: 394 pages|
Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Volume Seven, describes the fundamental aspects of efflux pumps of the ATP-binding cassette superfamily in cancer resistance pathways, along with strategies to target and improve chemotherapy efficacy. Pumps of the ATP-binding cassette superfamily (ABCs) regulate the access of drugs to the intracellular space. In this context, the overexpression of ABCs is a well-known mechanism of multidrug resistance in cancer and is associated with therapeutic failure. Cancer types discussed include breast, endocrine, hematologic, gastrointestinal, musculoskeletal, lung, skin and central nervous system cancers. The book is a valuable source for researchers and advanced students in cancer, biology, pharmacology, pharmaceutical sciences, biomaterials and medical/clinical sciences that are interested in accessing a comprehensive compendium on efflux pumps in mechanisms of cancer resistance. Offers comprehensive and detailed descriptions of the basic aspects of efflux pumps in a very schematic and didactic manner Describes the involvement of efflux pumps in cancer resistance in different cancer types Encompasses an updated overview on state-of-the-art approaches that capitalize on their inhibition to improve chemotherapy and overcome resistance
|Author||: Claudiu Supuran,Simone Carradori|
|Publisher||: Academic Press|
|Release Date||: 2020-09-15|
|ISBN 10||: 0128209283|
|Pages||: 228 pages|
pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field
|Author||: Andrew Freywald,Franco Vizeacoumar|
|Publisher||: Academic Press|
|Release Date||: 2020-12-04|
|ISBN 10||: 0128213116|
|Pages||: 308 pages|
Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies
Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field
|Author||: Benjamin Bonavida,Stavroula Baritaki|
|Publisher||: Academic Press|
|Release Date||: 2020-03-02|
|ISBN 10||: 0128196122|
|Pages||: 504 pages|
Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students. Provides an update from experts in the field on diagnostics, prognostics and therapeutics Brings a clear overview of recent findings and references, as well as summaries, significant molecular pathways, and conclusions in each chapter Provides a general introductory chapter on contributions in the field and a chapter summary, with synthesized findings and a projection of future goals
The Breast: Comprehensive Management of Benign and Malignant Diseases, 4th Edition, by Kirby I. Bland, MD, and Edward M. Copeland, III, MD, is a surgical reference that offers the most comprehensive, up-to-date resource on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast. With its multidisciplinary approach, sweeping updates, new contributors, and authoritative guidance, you’ll have exactly what you need to inspire patient confidence and provide the best possible outcomes. Features multidisciplinary advice from experts in surgery, radiation and medical oncology, pathology, molecular biology, pharmacokinetics, and genetics for a well-rounded perspective to enhance patient outcomes. Includes more than 1,500 figures and tables that offer high quality depictions of surgery and treatment procedures. Offers step-by-step guidance through both text and clinical boxes that makes the material relevant to everyday practice. Provides cross-referencing between chapters, as well as references to carefully selected journal articles, that makes further research easier. Uses a new full-color design to highlight key areas of the text and help you focus on important concepts. Presents updated coverage including an expanded section on pathology...and new chapters on granular cell tumors, targeted therapies, integration of radiotherapy and chemotherapy to keep you current. Includes revised chapters on the psychosocial consequences of breast cancer, lifestyle interventions for breast cancer patients, and patient and family resources that equip you to offer complete and compassionate care. Provides additional information on genetics to keep you up to date with the latest genetic discoveries linked to breast cancer and breast diseases. Features the work of many new contributors who provide the latest and freshest perspectives.
Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980’s with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due to early studies in the mouse skin carcinogenesis model, which showed that prolonged topical application of phorbol esters promoted the formation of skin tumors on mice previously treated with mutagenic agents. Research in the last years has established key roles for PKC isozymes in the control of cell proliferation, migration, adhesion, and malignant transformation. In addition, there is a large body of evidence linking PKC to invasion and cancer cell metastasis. Moreover, it is now well established that the expression of PKC isozymes is altered in various types of cancers. More importantly, small molecule inhibitors have been developed with significant anti-cancer activity. The relevance of PKC isozymes in cancer signaling is therefore remarkable. This book will have 4 sections. There will be 23 chapters. Each section will have a brief introduction by an expert in the field (~ 1-2 pages).
Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. The authors detail applications of combined modality therapy in lung, esophageal, breast, gastric, pancreatic, colon, and rectal cancers. They also show how radiation interacts with such chemotherapeutic agents as the platinum complexes, taxanes, and gemcitabine in the treatment of malignant gliomas, and head and neck cancer. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.
This book is intended for students and scientists working in the field of DNA repair. Select topics are presented here to illustrate novel concepts in DNA repair, the cross-talks between DNA repair and other fundamental cellular processes, and clinical translational efforts based on paradigms established in DNA repair. The book should serve as a supplementary text in courses and seminars as well as a general reference for biologists with an interest in DNA repair.
The importance of CK2 in cancer and other diseases has generated a significant amount of literature on the protein, and an international community of CK2 researchers. The International Union of Biochemistry and Molecular Biology (IUMBMB) sponsors periodic international conferences on CK2, making the protein a natural topic for a Wiley-IUBMB publication. Protein Kinase CK2 will deal with structural aspects underlying the constitutive activity of CK2, its specific susceptibility to pharmacological inhibition and its extraordinary pleiotropy. In the second part the fundamental role of CK2 in a w.
Much work over the last two decades has firmly established that loss of cell cycle checkpoint regulation, and resultant unabated cellular proliferation, is an inherent characteristic of cancer. This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint. In normal cells, checkpoint pathways are activated when genetic or cellular homeostasis is compromised, and signals are then transduced to re-stabilize homeostasis, and, failing this, to activate the apoptotic machinery to induce a cellular suicidal response. This implies that both survival and cell death pathways are induced following checkpoint activation, and that the final decision is dependant on the net result of integrating the two sets of signals. It is intriguing that checkpoint pathways are also critical in cancer therapy to provide an apoptotic stimulus when cellular damage induced by the therapeutic agent is detected by the sensor system. Therefore, it is not surprising that failure in pro-survival checkpoint response will render tumor cells hypersensitive to cytotoxics and, conversely, failure in pro-apoptotic checkpoint response will induce genetic instability and/or therapeutic resistance. Understanding the intricacies of checkpoint response is, therefore, central to the design of therapeutic regimen that will enhance antitumor effects. Although early versions of this design entail combination of cytotoxic agents with cell cycle or checkpoint inhibitors, a greater understanding of the concepts could make such combinations clinically more effective. The contributions in this book will consolidate the current state of knowledge on checkpoint responses that may lay the foundation for hypothesis-driven rational approaches in advancing the management of cancer. The immediate attraction of the book to the scientific community is that it represents a timely opportunity to build upon existing concepts of checkpoints to expand our understanding of the inner workings of the critical checkpoint machinery. The present understanding has provided ample appreciation that response to checkpoint activation is manifested through coordinated inhibition of cyclin-dependent kinase (CDK) complexes in G1, S and/or the G2 phase in order to arrest the cell cycle. Kinase inhibition can occur through several mechanisms, including inhibitory phosphorylation of CDK, destruction of the cognate cyclins, and recruitment of CDK inhibitors from the INK and WAF1/CIP1 families. However, the wealth of information from recent discoveries needs to be examined critically to consolidate our conceptual knowledge of checkpoints. At the same time, there is acute awareness in the diversity of checkpoint response between cytotoxic agents, and this serves as a reminder of the magnitude of complexity that is inherent in checkpoint regulation. This volume is intended to bring the cancer research community closer toward an improved understanding of this regulation, how checkpoint abnormalities can impact negatively on cancer therapy, and emerging strategies to target checkpoint response as a therapeutic end-point.
This book edition is intended to provide a concise summary for select topics in DNA repair, a field that is ever-expanding in complexity and biologic significance. The topics reviewed ranged from fundamental mechanisms of DNA repair to the interface between DNA repair and a spectrum on cellular process to the clinical relevance of DNA repair in oncologic paradigms. The information in this text should provide a foundation from which one can explore the various topics in depth. The book serve as a supplementary text in seminar courses with focus on DNA repair as well as a general reference for scholars with an interest in DNA repair.
Prominent investigators and clinicians summarize in a balanced blend of fundamental science, basic research, experimental therapeutics, and early clinical experiences, what is known about oncogenes and oncogenesis, and describe how that knowledge can be used to treat the cancer. The contributors explain how, why, and under what conditions certain proteins acquire the ability to transform eukaryotic cells, and detail the crucial biological consequences of this oncogenic transformation, particularly for cellular mitogenesis, survival, differentiation, migration, proteolysis, or angiogenic competence. Their articles thoroughly explicate the premises, principles, techniques, and approaches to oncogene targeting in various types of human cancer by using signal transduction inhibitors, immunological targeting methods, and antisense gene therapy.
|Author||: Ivor Benjamin,Robert C. Griggs,Thomas E. Andreoli,J. Gregory Fitz|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2010-04-06|
|ISBN 10||: 1437726739|
|Pages||: 1312 pages|
Students, residents, and instructors swear by Andreoli and Carpenter’s Cecil Essentials of Medicine because it presents just the right amount of information, just the right way. Edited by the late Thomas E. Andreoli, MD as well as Ivor Benjamin, MD, Robert C. Griggs, MD, and Edward J. Wing, MD, it focuses on core principles and how they apply to patient care, covering everything you need to know to succeed on a medical rotation or residency. Masterful editing and a user-friendly full-color design make absorbing and retaining information as effortless as possible. New chapters on "Pre- and Post-Operative Care" and "Palliative Care," plus the integration of molecular biology and other new horizons in medicine, familiarize you with the most current clinical concepts. An expanded International Editorial Board provides increased input from respected practitioners worldwide. Excellent images and clinical photographs vividly illustrate the appearance and clinical features of disease. Masterful editing and a user-friendly full-color design make absorbing and retaining information as effortless as possible.
|Author||: Nikolai Gorbunov,E. Marion Schneider|
|Publisher||: BoD – Books on Demand|
|Release Date||: 2016-11-10|
|ISBN 10||: 9535127268|
|Pages||: 526 pages|
Autophagy in Current Trends in Cellular Physiology and Pathology is addressed to one of the fundamental molecular mechanisms - autophagy- evolutionarily adopted by cells for processing of unnecessary or malfunctioned constituents and shaping intracellular structures, adjusting them to environmental conditions, aging, disease, neoplasia, and damages over their life period. Particular attention is paid to autophagy-mediated barrier processes of selective sequestration and recycling of impaired organelles and degradation of invading microorganisms, that is, the processes sustaining intrinsic resistance to stress, tissue degeneration, toxic exposures, and infections. The presented topics encompass personal experience and visions of the chapter contributors and the editors; the book chapters include a broad analysis of literature on biology of autophagy.
|Author||: Benjamin Bonavida|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2013-07-04|
|ISBN 10||: 1461470706|
|Pages||: 260 pages|
This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.
Colorectal cancer (CRC) is a major health problem because it represents around 10% of all cancers and achieves a worldwide estimate of 1.4 million newly diagnosed cases annually, resulting in approximately 700,000 deaths. Approximately 19-31% of patients present liver metastases. At diagnosis, a further 23-38% will develop extra-hepatic disease. Over the past decade, the widespread use of modern chemotherapeutic and biological agents, combined with laparoscopic surgical techniques, has improved the prognosis of metastatic CRC. A better understanding of the biology of the tumor, along with high efficiency of diagnostic and therapeutic methods, as well as the spread of screening programs, will improve the survival of the CRC patients in the near future.
|Author||: F. Stephen Hodi|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2014-09-19|
|ISBN 10||: 0323320333|
|Pages||: 225 pages|
This issue of Hematology/Oncology Clinics, guest edited by Dr. F. Stephen Hodi, is devoted to Melanoma. Articles in this issue include: The current state of Melanoma; Understanding the Biology of Melanoma Development and Therapeutic Implications; Surgical Management of Melanoma; Targeted Therapies for Cutaneous Melanoma; Treatments for Non-cutaneous Melanoma; Resistant Mechanisms and Therapeutic Implications; The Role of the Immune System in Melanoma Development and Treatment; Vaccines and Melanoma; IL-2, Interferon, and Cytokines; Immune Checkpoint Blockade; Adjuvant Treatments, Chance for Cure in Melanoma; and Combinatorial Approach to Treatment of Melanoma.